Drug Profile

Liradasertib - Denali Therapeutics

Alternative Names: BIIB-122; DNL-151

Latest Information Update: 08 Jul 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Genentech
Developer Biogen; Denali Therapeutics Inc
Class Antiparkinsonians; Small molecules
Mechanism of Action LRRK2 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase III Parkinson's disease

Most Recent Events

08 Jul 2026 Chemical structure information added
21 May 2026 Adverse events, efficacy and pharmacokinetics data from the phase-IIb LUMA trial in Parkinson's disease released by Biogen
21 May 2026 Biogen discontinues development of BIIB-122 for Parkinson's disease based on the results from Phase-IIb LUMA trial

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com